Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Monotherapy with the Novel Capsid Assembly Modulator ALG-000184 for up to 96 Weeks Results in Profound and Sustained HBV DNA Suppression in Untreated Subjects with Chronic HBV Infection

Wednesday, May 7, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the results of a study on ALG-000184, a novel capsid assembly modulator, which demonstrated profound and sustained suppression of HBV DNA in untreated subjects with chronic HBV infection over a treatment period of up to 96 weeks. This finding highlights the potential of ALG-000184 in managing chronic HBV infections effectively.
Price reaction · baseline $4.36 (2025-05-07 close) · hit after-hours · 5 other ALGS headline(s) in the window, move may be shared
day 0 close
+11.7%
day 1
+2.8%
day 3 · peak
+36.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Prolonged treatment with ALG-000184 shows significant HBV DNA suppression.
  • The study indicates potential for effective management of chronic HBV infection.
  • Results suggest sustained efficacy over a 96-week period.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-000184?

ALG-000184 is a novel capsid assembly modulator designed for chronic HBV treatment.

How long was the treatment period in the study?

The treatment period in the study lasted up to 96 weeks.

What were the results of the ALG-000184 study?

The study showed profound and sustained suppression of HBV DNA in untreated subjects.

Who were the subjects in the ALG-000184 study?

The subjects were untreated individuals with chronic HBV infection.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-000184 chronic HBV infection HBV DNA suppression biopharma clinical trials
Last updated: May 7, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →